MoonLake Immunotherapeutics 4

Chief Scientific Officer Kristian Reich indirectly sold 43,700 MoonLake Immunotherapeutics Class A ordinary shares at about $20.09 each under a Rule 10b5-1 plan.

On July 20, 2026, Chief Scientific Officer Kristian Reich, through indirect beneficial ownership via JeruCON Beratungsgesellschaft mbH, sold 43,700 Class A ordinary shares of MoonLake Immunotherapeutics at a weighted average price of approximately $20.09 per share under a pre-arranged Rule 10b5-1 trading plan, for total proceeds of about $878,000. Following this sale, Reich’s indirect holdings stood at 2,764,746 Class A ordinary shares, while his directly held position was 35,389 shares, indicating he retains a substantial ownership stake in the company despite the planned disposal.

Filing Facts

CIK

1821586

Ticker

MLTX

Form

4

Source Type

fda

Accession

0001213900-26-080133

Alert Tier

6